Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study

Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study

Plasma-based tumor mutational profiling is arising as a reliable approach to detect primary and therapy-induced resistance mutations required for accurate treatment decision making. Here, we compared the FDA-approved Cobas<sup>®</sup> EGFR Mutation Test v2 with the UltraSEEK™ Lung Panel...

Full description

Bibliographic Details
Main Authors: Pierre-Jean Lamy, Paul van der Leest, Nicolas Lozano, Catherine Becht, Frédérique Duboeuf, Harry J. M. Groen, Werner Hilgers, Nicolas Pourel, Naomi Rifaela, Ed Schuuring, Catherine Alix-Panabières
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
non-small cell lung cancer
EGFR mutation
circulating DNA
tyrosine kinase inhibitors
liquid biopsy
Online Access:https://www.mdpi.com/2072-6694/12/10/3002

Internet

https://www.mdpi.com/2072-6694/12/10/3002

Similar Items